Clinical TopicsOncologyUncategorizedWeb Exclusives

FDA expands use of Xalkori

Share

On March 11, the Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat people with metastatic non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. Read more

Test Your Knowledge

In what way does emotional intelligence affect nursing leaders in team and patient care settings?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts